TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stability of the shoe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scalp Hair Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with plasma HIV 1 RNA <50 copies/milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychiatric symptom domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of photoirritation and photosensitization
Endpoint domain: Adverse events/effects
Primary endpoint: adoption of community centers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Change From Baseline in Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Trail Making Test (TMT) B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Trail Making Test (TMT) A
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Trail Making Test (TMT) B - TMT A
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Residual Neuromuscular Blockade (NMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline to Week 4 in Blepharospasm Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain score over 72 hours post pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleurodesis success at 3 months post randomization (time to relapse of pleural effusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep dyspareunia score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lung cancer survival rate
Endpoint domain: Mortality/survival
Primary endpoint: LY03003 concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contracture Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Quality Indicators
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of subjects who serocovertize for HPV genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Emotional Overeating Questionnaire Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Positive and Negative Affect Schedule Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Word Sentence Association Paradigm Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pupil response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-O-desmethyl naproxen/naproxen ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the standardized core temperature * time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First attempt visualized blind intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day Pain Medication Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Achieving Chemical Castration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total cumulative amount of fluids infused
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dopamine release to food reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurotransmitter outcomes
Primary endpoint: postpolypectomy bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of 24-hour gastric pH above 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in Panel of Reactive Antibodies (PRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post intubation PaO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety variables
Endpoint domain: Adverse events/effects
Primary endpoint: Δ 2-h AUC C-peptide response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical and pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ankle Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concordance of Pap Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in glucose response (pAUC) to mixed meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse events of local and systemic reactions within 30 minutes after each dose
Endpoint domain: Adverse events/effects
Primary endpoint: All active adverse events within 0-7 days after each dose
Endpoint domain: Adverse events/effects
Primary endpoint: All serious adverse events within 6 months after the first dose is vaccinated
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinical symptoms of neurological disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aδ:C Fiber Detection Threshold Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone-Renin Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reaction Time for Simple Reaction Time Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Life Assessment for Caregivers of Patients With Alzheimer's Disease (QoL-AD) Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life Assessment for Patients With Alzheimer's Disease (QoL-AD) Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IV Morphine consumption in phase 1 recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success (absence of live lice)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Healing of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lung Clearance Index 2%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Substance Use Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of EBV nucleic acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Asthma Control Questionnaire (ACQ) symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pathologic response evaluated by Evans grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Exhaled NO Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sexual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Based on RECIST V1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of AERAS-402 followed by MVA85A
Endpoint domain: Adverse events/effects
Primary endpoint: Past caries experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Fungal-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of protected penile-vaginal sex acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of SAEs and Treatment-related Severe AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of ROSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Desaturation Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Respond to the Survey in Week 1
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Number of Questions to Which Participant Respond in Each Survey in Week 1
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Number of Hours From Sending a Survey to Participants to Receiving Their Response in Week 1
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: QT/QTc prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight for Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4 T cell PD1+TIGIT+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects achieving clear or almost clear SPGA score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correlation of clinical-volumetric pathologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in 3-point chuck strength at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Lateral pinch strength at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) for Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PROMIS Upper Extremity CAT at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change in Frequency of Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC0-72h: flupentixol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: flupentixol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72h: melitracen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: melitracen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in average UOP (urine output)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in average AOP (arterial oxygen pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Major Adverse Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nocturnal Mean Arterial Blood Pressure (NMAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychosomatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-reported Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sub-bandage pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Neurologic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically Significant Treatment-Emergent ECG Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Symptoms of Sickle Cell Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory Test Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large for gestational age or macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in disease activity (PUCAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTS symptom severity score after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Carcinomatous invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects experiencing severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: neutrophil populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of percutaneous tracheostomy
Endpoint domain: Adverse events/effects
Primary endpoint: percent change from baseline in urine N-telopeptide (NTx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Internal and external satiety calories consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum QTF Following Ibutilide 0.003 mg/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Percent Change From Pretreatment Value in QTF Following Ibutilide 0.003 mg/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Maximal Force Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in minimal hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Occurrences of Cardio-vascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drain Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin reflex distance (MRD1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Postoperative Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Lipid Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Helicobacter Pylori Eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tremor severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HBA1C level (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Healthcare providers' knowledge and attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major adverse events (cerebral infarct, death) in 30 days post the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Complete occlusion rate at 6 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serum HBV DNA < 1000 Copies/mL and Normal ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal change esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Text reading accuracy expressed in number of errors change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Text reading speed expressed in syllables per seconds change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word reading speed expressed in syllables per seconds change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of wound healing of pressure sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of life (psycho-sexual)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful engraftment of donor fecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consolidation of the fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of HCV care milestones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plantar flexion while ambulating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Data accuracy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Late airway response (LAR) area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Salivary Streptococcus Mutans Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: angiographic luminal patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion visibility on PAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS Symptom Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale (NRS) change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Function IndeX for Trauma (FIX-IT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Union Score for Tibial Fractures (RUST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of C-terminal Telopeptide of Type I Collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of N-terminal Propeptide of Type I Procollagen (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in dyspnoea domain of the CRQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement of Melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in X-ray quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change to the quality of life over 1 year following surgery based on the EQ5-D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence Rate of Treatment Resistant Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Resistant Depression as a Proportion of Pharmacologically Treated Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25-OH-D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Zung Self-Rating Anxiety Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Interventions Used to Complete Bowel Routine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Event-free Survival After 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: physician ratings of misuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structured self-report interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: urine tox screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without PSA-progression at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in chest wall dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lens Orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Context Dependent Motor Learning (CDML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes